- By Joergen Haisem
- (General Dispatch) – Johnson & Johnson’s single-dose covid-19 vaccine was recommended by the European Medicines Agency (EMA).
- After conducting detailed investigations, the EU drug regulator determined that the vaccine should be authorized and given to people over 18 years of age.
- However, the vaccine used by Johnson & Johnson was found to be effective, safe and of high quality, according to members of the drug regulatory agency.
- In contrast, the vaccines developed by Pfizer and AstraZeneca require the delivery of two doses at different times, representing a disadvantage in the face of an emergency.
- Subsequently, the introduction of the vaccine to the market, in principle, would have 1,800 million doses to be distributed. With an effectiveness of at least 67%, causing only fatigue and some pain in the applied area.
- The European Union is currently trying to immunize most of its 27 member countries to guarantee the welfare of its citizens.
- However, the progress made with the vaccine has not stopped the rate of infection, which is progressively increasing. Europe has once again recorded 1 million cases, which represents a 9% increase compared to the previous week.
- The challenge for Johnson & Johnson is to accelerate its production process in view of the remarkable demand, for which pharmaceutical agreements have been established to contribute to the progress of the vaccine against covid-19.
Adittional Information:
Breitbart: EU regulator recommends using J&J’s one-shot vaccine
AP News: EU regulator recommends using J&J’s one-shot vaccine
